Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis
- PMID: 2683800
- PMCID: PMC1880110
Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis
Abstract
Anti-neutrophil cytoplasmic autoantibodies (ANCA) react with constituents of neutrophil primary granules and monocyte lysosomes. Indirect immunofluorescence microscopy using alcohol-fixed neutrophils demonstrates two ANCA types: one causing cytoplasmic staining (C-ANCA), and a second causing artifactual perinuclear staining (P-ANCA) that frequently has specificity for myeloperoxidase. Using indirect immunofluorescence microscopy (IIFM) and enzyme immunoassays (EIA), sera from over 300 patients with renal disease, with and without systemic vasculitis, were analyzed. Of 76 patients with pauci-immune glomerulonephritis with crescents or necrosis, 87% had ANCA by IIFM (38% of C-ANCA type, 49% of P-ANCA type), and 78% had ANCA by EIA. Of 55 patients with nonlupus immune complex-mediated glomerulonephritis, only 11% had ANCA by IIFM and 5% had ANCA by EIA. Of 24 patients with anti-GBM antibody-mediated glomerulonephritis, none had ANCA. Renal and extrarenal lesions were studied in 81 patients with ANCA-associated glomerulonephritis. These patients formed a pathologic continuum ranging from renal-limited to widespread systemic vascular injury, including patients with primary crescentic glomerulonephritis, Wegener's granulomatosis, and polyarteritis nodosa. In ANCA-positive patients the frequency of C-ANCA and P-ANCA correlated with disease distribution. P-ANCA was most frequent with renal-limited disease and C-ANCA was most frequent when there was lung and sinus involvement. It is proposed that ANCA are not only useful diagnostic markers, but may also be directly involved in a novel pathogenetic mechanism that is a frequent cause of crescentic glomerulonephritis and systemic necrotizing vasculitis.
Similar articles
-
Antineutrophil cytoplasmic autoantibodies and associated diseases: a review.Am J Kidney Dis. 1990 Jun;15(6):517-29. doi: 10.1016/s0272-6386(12)80521-x. Am J Kidney Dis. 1990. PMID: 1973331 Review.
-
[Anti-neutrophil cytoplasmic autoantibody (ANCA) in systemic vasculitic syndrome].Rinsho Byori. 1993 Aug;41(8):866-75. Rinsho Byori. 1993. PMID: 8371502 Review. Japanese.
-
Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.Ann Intern Med. 1990 Nov 1;113(9):656-63. doi: 10.7326/0003-4819-113-9-656. Ann Intern Med. 1990. PMID: 2221646
-
Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.N Engl J Med. 1988 Jun 23;318(25):1651-7. doi: 10.1056/NEJM198806233182504. N Engl J Med. 1988. PMID: 2453802
-
[Rapidly progressive glomerulonephritis without immune deposits: detection of neutrophil anticytoplasmic antibodies].Rev Med Chil. 1993 Mar;121(3):260-4. Rev Med Chil. 1993. PMID: 8248637 Spanish.
Cited by
-
Reactive oxygen molecules, oxidant injury and renal disease.Pediatr Nephrol. 1991 Nov;5(6):733-42. doi: 10.1007/BF00857888. Pediatr Nephrol. 1991. PMID: 1662982 Review.
-
Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Compared to Systemic Lupus Erythematosus.Arthritis Rheumatol. 2019 Dec;71(12):2047-2058. doi: 10.1002/art.41047. Epub 2019 Nov 9. Arthritis Rheumatol. 2019. PMID: 31313503 Free PMC article.
-
Cells perpetuating the inflammatory response in scleritis.Br J Ophthalmol. 1994 May;78(5):381-5. doi: 10.1136/bjo.78.5.381. Br J Ophthalmol. 1994. PMID: 8025072 Free PMC article.
-
Differences in Radiological and Pathological Findings by ANCA-Subtype in ANCA-Positive Idiopathic Interstitial Pneumonias.Clin Respir J. 2025 Mar;19(3):e70061. doi: 10.1111/crj.70061. Clin Respir J. 2025. PMID: 40070290 Free PMC article.
-
Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation.Life (Basel). 2025 May 8;15(5):756. doi: 10.3390/life15050756. Life (Basel). 2025. PMID: 40430184 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials